The Confirmatory Olmesartan Plaque Regression Study (CONFIRM)
Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Terminated
Low recruitment
Other terminated trials from Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See all terminations from Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
A PHASE4 clinical study on Carotid Plaque and Essential Hypertension, this trial is terminated or withdrawn. The trial is conducted by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company and has accumulated 10 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Mar 2024 [monthly]
Terminated PHASE4
-
Jan 2019 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 5 earlier versions
-
Jul 2018 — Jan 2019 [monthly]
Terminated PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Terminated PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Feb 2017 — Sep 2017 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
May 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
For direct contact, visit the study record on ClinicalTrials.gov .